Susquehanna International Group’s Foghorn Therapeutics FHTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-30,100
Closed -$212K 12284
2023
Q2
$212K Buy
+30,100
New +$210K ﹤0.01% 10158
2023
Q1
Sell
-35,900
Closed -$229K 12830
2022
Q4
$229K Sell
35,900
-1,100
-3% -$8.29K ﹤0.01% 9781
2022
Q3
$317K Buy
+37,000
New +$476K ﹤0.01% 9653
2022
Q1
Sell
-41,400
Closed -$947K 13271
2021
Q4
$947K Buy
+41,400
New +$595K ﹤0.01% 7445

Other funds holding FHTX

Susquehanna International Group's FHTX Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Foghorn Therapeutics (FHTX) in Q1 2026: 11,637 shares worth $55.6K. The stake represents ﹤0.01% of the portfolio and ranks #12608 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in FHTX as recently as Q2 2025.

Susquehanna International Group first reported a position in FHTX in Q4 2020 and has held it in 11 quarters since. The position peaked at $566K in Q4 2020. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Susquehanna International Group held 11,637 shares of Foghorn Therapeutics worth $55.6K as of Q1 2026.
  • Foghorn Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Foghorn Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12608 holding.
  • Susquehanna International Group first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • Susquehanna International Group's Foghorn Therapeutics position peaked at $566K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.